ClinicalTrials.gg
CompletedNCT05994534INCAUpdated Oct 13, 2026

PK and PD Study of NPI-001 and Cysteamine Bitartrate

A Phase 1/2 interventional study of Cysteamine Bitartrate and N-Acetylcysteine Amide in Cystinosis, sponsored by Nacuity Pharmaceuticals, Inc.. Completed at 1 site in Australia. Open to participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Nacuity Pharmaceuticals, Inc. · Phase 1/2, Interventional, and Treatment

Updated Oct 13, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
8
Allocation
Non-randomized
Ages
10 Years and older
Sex
All
01

Study summary

Safety, pharmacokinetics, and pharmacodynamics of NPI-001 oral solution in cystinosis patients compared with cysteamine.

Read the detailed description

This study will examine the safety, pharmacokinetics, and pharmacodynamics of NPI-001 oral solution in cystinosis patients, aged ≥ 10 years. The ability of NPI-001 to reduce cystine will be assessed and compared with cysteamine.

02

Conditions studied

  • Cystinosis

Browse trials for

03

In context

Cystinosis

47 studies on the registry are indexed under Cystinosis; 15 are open to participants now.

This study's enrollment of 8 is below the median of 30 across 27 interventional studies indexed under Cystinosis.

Browse Cystinosis studies →

Lead sponsor

Nacuity Pharmaceuticals, Inc. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females, any race, ≥ 10 years of age.
  2. Diagnosis of nephropathic cystinosis and able to cease cysteamine therapy for 2 days.
  3. Females will be nonpregnant and nonlactating, and females of and males will agree to use as detailed in the protocol.
  4. Able to comprehend and willing to sign an /assent form and to abide by the study restrictions (travel as necessary, clinical phase 1 unit or similar for up to 3 days).

Exclusion criteria

Exclusion Criteria:

  1. Have undergone kidney transplantation.
  2. Are receiving dialysis treatment.
  3. History of significant to NAC or any ingredient of NPI-001 oral solution.
  4. Participation in a clinical study involving administration of an drug (new chemical entity) in the 30 days prior to Day 1.
  5. Inability to provide blood samples, including difficulty with venous access.
  6. Subjects who, in the opinion of the Investigator and/or Sponsor (or designee), should not participate in this study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Active comparator
    cysteamine

    Single dose, tablets in current treatment dose

    Drug: Cysteamine Bitartrate

  • Experimental
    NPI-001

    Single dose, NPI-001 (N-acetylcysteine amide) oral solution at molar equivalent of current cysteamine dose.

    Drug: N-Acetylcysteine Amide

Interventions

06

What researchers measure

Primary outcomes

  1. Concentration of Cystine Levels Over Time

    Cystine concentration over 6 hours

    Time frame: 1 day

07

Study locations

1 site
  • Children's Hospital at Westmead
    Westmead, New South Wales 2145, Australia
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be made available to other researchers.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Oct 2023 to primary completion in May 2026, 30 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Aug 2026 → May 2026 and completion Aug 2026 → May 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2023
First posted
Aug 16, 2023
StartActual
Oct 29, 2023
Primary completionActual
May 26, 2026was Aug 2026
CompletionActual
May 26, 2026was Aug 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 13, 2026
Primary completion
Aug 2026→May 26, 2026 (actual)
Oct 13, 2026
Study completion
Aug 2026→May 26, 2026 (actual)
Oct 13, 2026
Enrollment
12 (estimated)→8 (actual)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Active, not recruiting→Completed
    Primary completion Aug 2026→May 26, 2026 (now actual)
    Study completion Aug 2026→May 26, 2026 (now actual)
    Enrollment 12 (estimated)→8 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05994534
Lead sponsor
Nacuity Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Aug 16, 2023
Start date
Oct 29, 2023
Primary completion
May 26, 2026
Completion
May 26, 2026
Last update
Oct 13, 2026

Study contacts

Hugh McCarthy, PhD, FRACP
principal investigator · Sydney Children's Health Network

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: N-Acetylcysteinamide

Start the discussion